129 related articles for article (PubMed ID: 38423788)
1. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma.
Lin F; Clift R; Ehara T; Yanagida H; Horton S; Noncovich A; Guest M; Kim D; Salvador K; Richardson S; Miller T; Han G; Bhat A; Song K; Li G
J Nucl Med; 2024 Apr; 65(4):586-592. PubMed ID: 38423788
[TBL] [Abstract][Full Text] [Related]
2. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
3. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3-Targeted
Labadie KP; Hamlin DK; Kenoyer A; Daniel SK; Utria AF; Ludwig AD; Kenerson HL; Li L; Sham JG; Chen DL; Orozco JJ; Yeung RS; Orvig C; Li Y; Wilbur DS; Park JO
J Nucl Med; 2022 Jul; 63(7):1033-1038. PubMed ID: 34772791
[TBL] [Abstract][Full Text] [Related]
5. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
Fayn S; King AP; Gutsche NT; Duan Z; Buffington J; Olkowski CP; Fu Y; Hong J; Sail D; Baidoo KE; Swenson RE; Cheloha RW; Ho M; Choyke PL; Escorcia FE
J Nucl Med; 2023 Jul; 64(7):1017-1023. PubMed ID: 36997331
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
[TBL] [Abstract][Full Text] [Related]
10. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
[TBL] [Abstract][Full Text] [Related]
11. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
12. The development of a Glypican-3-specific binding peptide using
Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X
Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851
[TBL] [Abstract][Full Text] [Related]
13. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
An S; Zhang D; Zhang Y; Wang C; Shi L; Wei W; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2682-2692. PubMed ID: 35147737
[TBL] [Abstract][Full Text] [Related]
14. Development and
Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 targeted delivery of
Labadie KP; Ludwig AD; Lehnert AL; Hamlin DK; Kenoyer AL; Sullivan KM; Daniel SK; Mihailovic TN; Sham JG; Orozco JJ; Yeung RS; Chen DL; Wilbur DS; Miyaoka RS; Park JO
Sci Rep; 2021 Feb; 11(1):3731. PubMed ID: 33580090
[TBL] [Abstract][Full Text] [Related]
16. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
Filmus J; Capurro M
FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
[TBL] [Abstract][Full Text] [Related]
18. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
19. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
